Ticker Price Type Catalyst Date (due by) Catalyst Notes - click for details
ACHN 12.37 Phase 2 04/15/2012 Phase 2 complete data of ACH-1625 for HCV due April. April 15 estimate only using midpoint.
AEGR 14.75 NDA filing 03/31/2012 NDA filing of Lomitapide for homozygous familial hypercholesterolemia 1Q 2012
AEGR 14.75 Phase 3 12/31/2012 Phase 3 initiation of Lomitapide for familial chylomicronemia sometime 2012
AEZS 1.65 Phase 3 03/31/2012 Complete Phase 3 Perifosine for metastatic colorectal cancer 1Q 2012
AEZS 1.65 NDA filing 12/31/2012 NDA filing for diagnostic test for Adult Growth Hormone Deficiency (AGHD) likely sometime 2012
AFFY 7.09 PDUFA 03/27/2012 PDUFA 3/27/2012 of Peginesatide for Anemia in chronic renal failure (CRF)
AIS 2.19 NDA filing 12/31/2012 NDA filing of VIBEX for Rheumatoid arthritis (RA) during 2012
ALKS 18.16 PDUFA 01/28/2012 PDUFA 1/28/12 of BYDUREON for Type 2 diabetes
ALKS 18.16 Phase 2 06/30/2012 Phase 2b data of Opioid-induced constipation mid-2012
ALKS 18.16 Phase 3 06/30/2013 Pivotal ALKS 9070 in patients with schizophrenia data due mid 2013
ALKS 18.16 Phase 2 06/30/2013 Phase 2 data ALKS 5461 for Depression due 1H 2013
ALNY 9.88 Phase 2 06/30/2012 Phase 2b data for RSV (respiratory syncytial virus) infected adult lung transplant patients due mid 2012)
ALNY 9.88 Phase 2 12/31/2012 Phase 2 initiation of ALN-TTR02 for Transthyretin-mediated amyloidosis (ATTR) during 2H 2012
ALTH 1.55 Phase 1/2 06/30/2012 Phase 1/2 FOLOTYN data 2nd line Non-Hodgkin Lymphoma combination Pralatrexate + Gemcitabine 1H 2012
ALTH 1.55 Phase 2 12/31/2012 Phase 2 Bladder Cancer Data expected sometime in 2012
ALTH 1.55 Phase 2 12/31/2012 Phase 2 Breast Cancer Data expected sometime in 2012
ALXA 0.80 PDUFA 02/04/2012 PDUFA 2/4/12 of Staccato loxapine for Schizophrenia
AMLN 11.79 PDUFA 01/28/2012 PDUFA 1/28/12 of BYDUREON for Type 2 diabetes
AMLN 11.79 BLA filing 06/30/2012 Submit final part of BLA for Lipodystrophy by 1H 2012
AMRN 7.17 PDUFA 07/26/2012 PDUFA 7/26/12 of AMR101 for very high triglyceride levels
AMRN 7.17 12/31/2012 Initiation of REDUCE-IT cardiovascular outcomes trial by end of 2012
ANTH 7.01 Phase 2 03/31/2012 Phase 3 Vista 16 trial for Acute Coronary Syndrome - accrue the final event during Q1 2012
ANTH 7.01 Phase 2 06/30/2012 Phase 2b top-line data of PEARL-SC trial for lupus due 2Q 2012
ANX 0.61 Phase 3 12/31/2012 Phase 3 initiation for Sickle cell disease during 2012
APPA 0.26 Safety trial 03/31/2012 Data of QT study designed to support NDA of APF530 due 1Q 2012
APPA 0.26 NDA filing 06/30/2012 NDA filing of APF530 due 1H 2012 for patients with chemotherapy-induced nausea and vomiting
ARIA 14.42 PDUFA 06/05/2012 PDUFA June 5 2012 of ridaforolimus for metastatic soft-tissue or bone sarcomas
ARIA 14.42 NDA filing 09/30/2012 NDA filing of Oral ponatinib for chronic myeloid leukemia, acute lymphoblastic leukemia due 3Q 2012
ARIA 14.42 Phase 2 12/31/2012 Phase 2 AP26113 for NSCLC to be initiated 2H 2012
ARNA 1.65 PDUFA 06/27/2012 PDUFA date June 27 2012 for lorcaserin in patients with obesity
ARQL 5.96 Phase 2 03/31/2012 Phase 2 data Tivantinib (ARQ 197) hepatocellular carcinoma (HCC) due early 2012
ARRY 2.38 Phase 2 06/30/2012 Phase 2 topline data of ARRY 797 for pain due 1H 2012
ARRY 2.38 Phase 2 06/30/2012 Phase 2 initiation of ARRY 502 for asthma 1H 2012
ASTM 1.87 Phase 3 01/31/2012 Phase 3 critical limb ischemia (CLI) to be January 2012
ASTM 1.87 Phase 2 06/30/2012 Initiate Phase 2b ixmyelocel-T for DCM in 1H 2012
ASTX 2.08 Advisory Committee 02/09/2012 Advisory Committee Meeting 2/9/12 of sNDA of Dacogen for Acute myeloid leukemia (AML)
ASTX 2.08 PDUFA 03/06/2012 PDUFA 3/6/12 of sNDA of Dacogen for Acute myeloid leukemia (AML)
ASTX 2.08 Phase 2 12/31/2012 Phase 2 data of SGI-110 for AML/MDS due late 2012
AVEO 14.83 NDA filing 09/30/2012 NDA for tivozanib in patients with advanced renal cell carcinoma due to be filed 3Q 2012
AVEO 14.83 Phase 2 12/31/2012 Phase 2 Topline data of ficlatuzumab in both wild-type and mutant EGFR non-small cell lung cancer due sometime in 2012
BCRX 2.85 Phase 3 06/30/2012 Phase 3 Peramivir - Interim analysis due by mid 2012
BPAX 0.54 PDUFA 02/14/2012 PDUFA 2/14/12 of Bio-T-Gel for male hypogonadism
CBRX 2.40 Advisory Committee 01/20/2012 AdCom meeting 1/20/12 of of PROCHIEVE for reduction of risk of preterm birth
CBRX 2.40 PDUFA 02/26/2012 PDUFA 2/26/12 of PROCHIEVE for reduction of risk of preterm birth
CHTP 5.06 Advisory Committee 02/23/2012 Adcom Meeting for NORTHERA(TM) for the Treatment of Symptomatic NOH Feb 23 2012
CHTP 5.06 PDUFA 03/28/2012 PDUFA 3/28/2012 of Northera for Neurogenic Orthostatic Hypotension
CHTP 5.06 Phase 2 06/30/2012 Phase 2 topline data for Rheumatoid Arthritis due 2Q
CLDX 3.15 Phase 2 06/30/2012 Phase 2b data of CDX-011 Metastatic breast due 1H 2012 at a scientific conference
CLSN 1.73 Phase 3 12/31/2012 Phase 3 ThermoDox for liver cancer 380 PFS Events Projected to Occur in Late 2012
CORT 3.14 PDUFA 02/17/2012 PDUFA 2/17/12 of Korlym for Cushing's Syndrome
CPRX 1.19 Phase 2 12/31/2012 Phase 2b Top-line data trial evaluating CPP-109 for the treatment of cocaine addiction due 4Q 2012
CRIS 4.52 PDUFA 03/08/2012 PDUFA 3/8/12 of vismodegib for Advanced Basal Cell Carcinoma under priority review
CTIC 1.15 Advisory Committee 02/09/2012 FDA Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone for NHL on 2/9/12
CTIC 1.15 PDUFA 04/24/2012 PDUFA 4/24/12 of resubmission of Pixantrone for NHL
CTIC 1.15 Phase 3 06/30/2012 Initiate Phase 3 Tosedostat for AML 2Q 2012
CTIC 1.15 Phase 2 06/30/2012 Phase 2 Data Pixantrone for breast cancer due mid 2012
CTIC 1.15 Phase 3 06/30/2012 Phase 3 interim analysis of OPAXIO for ovarian cancer due mid 2012
CXM 0.36 Phase 3 03/31/2012 Phase 3 initiation of Generx Russian trial 1Q 2012
CYTK 1.01 Phase 2 06/30/2012 Phase 2 CK-2017357 for myasthenia gravis due 1H 2012
CYTK 1.01 Phase 2 06/30/2012 Phase 2b initiation of CK-2017357 for Amyotrophic Lateral sometime 2012
DARA 1.30 Phase 2 12/31/2011 Initiate 2nd Phase 2 KRN5500 for Chemotherapy-Induced Neuropathic Pain in Patients With Cancer by end of 2011
DCTH 4.16 NDA filing 06/30/2012 NDA filing for the treatment of patients with metastatic melanoma in the liver during 2Q 2012
DSCO 2.26 PDUFA 03/06/2012 PDUFA 3/6/12 of Surfaxin for Respiratory Distress Syndrome
DVAX 3.69 NDA filing 03/31/2012 File BLA for HEPLISAV for persons over 40 years of age 1Q 2012
DYAX 1.39 Phase 2 12/31/2012 Phase 2 data of Ecallantide for ACE Inhibitor-Induced Angioedema due 2H
ECYT 3.59 Phase 2 03/31/2012 Phase 2 initiation of EC145 for NSCLC 1Q 2012
EXEL 4.96 Phase 3 12/31/2011 Phase 3 initiation of Castration-Resistant Prostate Cancer - 306 trial late 2011
EXEL 4.96 Phase 3 06/30/2012 Phase 3 initiation of Castration-Resistant Prostate Cancer - 2nd Phase 3 307 trial, 1H 2012
FOLD 5.01 Phase 2 06/30/2012 Complete Phase 2 trial of Migalastat co-administered with enzyme replacement therapy (ERT) for Fabry disease (Study 013) during 1H 2012
FOLD 5.01 Phase 2 06/30/2012 Phase 2 preliminary data of AT2220 co-administered with the ERT alglucosidase alfa in patients with Pompe Disease due 1H 2012
FOLD 5.01 Phase 3 09/30/2012 Phase 3 data (Study 011) of migalastat HCl for Fabry disease due 3Q 2012.
FOLD 5.01 Phase 3 12/31/2012 Phase 3 enrolment of Migalastat HCl monotherapy for Fabry Disease due to be completed by end of 2012.
FURX 15.98 PDUFA 04/25/2012 PDUFA 4/25/2012 of Alogliptin for Type 2 diabetes
GALE 0.68 Phase 3 06/30/2012 Phase 3 initiation of NeuVax (E75) under SPA for low-to-intermediate HER2+ breast cancer 1H 2012
GERN 1.69 Phase 2 12/31/2012 Phase 2 initiation of GRN1005 for GBM 2012
GERN 1.69 Phase 2 12/31/2012 Phase 2 Topline data of Imetelstat for breast cancer due by end of 4Q 2012
GERN 1.69 Phase 2 12/31/2012 Phase 2 Topline data of Imetelstat for multiple myeloma due by end of 4Q 2012
GERN 1.69 Phase 2 12/31/2012 Phase 2 Topline data of Imetelstat for breast cancer due by end of 4Q 2012
GERN 1.69 Phase 2 12/31/2012 Phase 2 Topline data of Imetelstat for essential thrombocythemia due by end of 4Q 2012
GERN 1.69 Phase 2 06/30/2013 Phase 2 GRN1005 data of brain metastases arising from breast cancer due mid 2013
GERN 1.69 Phase 2 06/30/2013 Phase 2 GRN1005 data of brain metastases arising from NSCLC due mid 2013
GTXI 3.87 Phase 2b 03/31/2012 Phase 2b data likely from dose finding and maintenance dose finding trials of GTx-758 Capesaris for advanced prostate cancer likely due 1Q 2012.
HALO 9.80 Phase 1/2 03/31/2012 Discuss top line results from a Phase 1/2 study with HTI-501 in women with moderate to severe cellulite - 1H 2012
HALO 9.80 Phase 3 06/30/2012 Complete Phase 2 study with Viropharma for SC Cinryze - 1H 2012
HALO 9.80 Phase 3 12/31/2012 Present HannaH Phase 3 clinical trial data - sometime in 2012
HALO 9.80 NDA filing 12/31/2012 Regulatory Submission Herceptin SC - sometime in 2012
HALO 9.80 NDA filing 12/31/2012 Regulatory Submission Mabthera SC - sometime in 2012
HGSI 8.86 Phase 3 06/30/2012 Initial Phase 3 data of Albiglutide for Type 2 diabetes due mid 2012
HGSI 8.86 Phase 3 12/31/2012 Phase 3 initiation of Benlysta for Vasculitis sometime during 2012
HGSI 8.86 Phase 3 12/31/2012 Phase 3 initiation of Benlysta for Active lupus nephritis sometime during 2012
HGSI 8.86 Phase 2 12/31/2012 Phase 2 enrolment of Mapatumumab with sorafenib for cardiovascular disease sometime during 2012
HGSI 8.86 Phase 3 12/31/2014 Phase 3 data of Subcutaneous BENLYSTA for lupus due 2H 2014
HZNP 3.55 PDUFA 07/26/2012 PDUFA 7/26/12 of LODOTRA for rheumatoid arthritis
IDRA 1.1 Phase 2 06/30/2012 Initiate Phase 2 IMO-3100 for Psoriasis during 1H 2012
IDRA 1.10 Phase 2 12/31/2012 Phase 2 data for NSCLC due 2012
IMGN 12.28 Phase 2 03/31/2012 Phase 2 initial data of IMGN901 lorvotuzumab mertansine for small-cell lung cancer SCLC early 2012
IMGN 12.28 Phase 3 06/30/2012 Phase 3 data for Trastuzumab emtansine for 2nd-line HER2+ breast cancer due by mid-2012
IMGN 12.28 Phase 2 12/31/2012 Phase 2 Data of IMGN901 lorvotuzumab mertansine for small-cell lung cancer SCLC due 2H 2012
IMMU 3.45 Phase 3 12/31/2012 Phase 3 initiation of 90Y-clivatuzumab tetraxetan in patients with advanced pancreatic cancer sometime 2012 pending funding
INFI 8.99 Phase 2 12/31/2012 Phase 2 enrolment of Retaspimycin Hydrochloride with docetaxel for NSCLC to be completed 2H 2012
INFI 8.99 Phase 2 12/31/2012 Phase 1b/2 Retaspimycin Hydrochloride with docetaxel topline data of dose-escalation portion of the Phase 1b/2 trial for NSCLC due 2H 2012
INFI 8.99 Phase 2 12/31/2012 Phase 2 topline data of IPI-926 Saridegib for Pancreatic Cancer due 2H 2012
INFI 8.99 Phase 2 12/31/2012 Phase 2 topline data of Saridegib for Myelofibrosis due 2H 2012
INFI 8.99 Phase 2 12/31/2012 Phase 2 enrolment of IPI-926 Saridegib for Chondrosarcoma complete 2H 2012
IPXL 20.17 Phase 2b 06/30/2013 Phase 2b data of IPX159 for restless legs due mid 2013
IRWD 12.10 PDUFA 06/09/2012 PDUFA date early June 2012 for irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC) - exact date TBC
ISIS 7.60 NDA filing 03/31/2012 NDA mipomersen for Homozygous familial hypercholesterolemia (HoFH) 1Q 2012
ISTA 7.27 NDA filing 06/30/2012 NDA filing of PROLENSA for Postoperative inflammation and reduction of ocular pain post-cataract extraction due 1H 2012
ISTA 7.27 Phase 2 06/30/2012 Phase 2 data of BEPOSONE for Seasonal allergic rhinitis due 1H 2012
ISTA 7.27 Phase 3 12/31/2012 Phase 3 initiation of T-PRED for Uveitis and allergic conjunctivitis during 2H 2012
ITMN 15.32 Phase 3 06/30/2012 Phase 3 enrolment due to be completed 1H 2012 for Pirfenidone for Idiopathic pulmonary fibrosis
KERX 2.66 Phase 3 03/31/2012 Complete Phase 3 Perifosine for metastatic colorectal cancer 1Q 2012
LGND 12.09 NDA filing 12/31/2011 NDA filing of Aprela for Menopausal symptoms due 4Q 2011
LGND 12.09 Phase 3 03/31/2012 Initiate pivotal trial of Captisol-Enabled Melphalan for multiple myeloma 1Q
LGND 12.09 NDA filing 06/30/2012 sNDA of Promacta/Revolade for HCV due to be filed 2Q 2012
LLY 39.94 PDUFA 01/28/2012 PDUFA 1/28/12 of BYDUREON for Type 2 diabetes
LXRX 1.46 Phase 2 12/31/2011 Initiate Phase 2 trial of LX1032 for ulcerative colitis 4Q
LXRX 1.46 Phase 2 06/30/2012 Phase 2b data of LX4211 for diabetes due mid 2012
MAPP 13.79 PDUFA 03/26/2012 PDUFA 3/26/12 of LEVADEX for Migraine
MDVN 55.72 Phase 3 06/30/2012 Phase 3 Dimebon CONCERT Huntington disease trial data due 1H
MITI 8.82 Phase 2 12/31/2012 Phase 2 enrolment of Blinatumomab for relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) due to be completed by end of 2012
MNOV 1.85 Phase 2 03/31/2012 Phase 2 completion of MN-221-CL-007 for acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations due 1Q 2012
NAVB 2.79 PDUFA 06/10/2012 PDUFA 6/10/12 for Lymphoseek - Lymphatic-tissue tracing agent
NBIX 8.61 Phase 3 03/31/2012 Initiate Phase 3 Elagolix for endometriosis 2012 under SPA - 1Q 2012 estimate only
NBIX 8.61 Phase 2 03/31/2012 Phase 2b data of VMAT2 inhibitor, NBI-98854 for Tardive Dyskinesia due 1Q 2012)
NBY 1.39 Phase 2 12/31/2011 Start Ph2b NVC422 for Impetigo skin infection 4Q 2011, data 2H 2012
NBY 1.39 Phase 2 03/31/2012 Prelim Phase 2 data NVC422 for urinary infection 1Q 2012
NBY 1.39 Phase 2 03/31/2012 Initiate Phase 2b Viral conjunctivitis 1Q 2012
NBY 1.39 Phase 2 12/31/2012 Ph2b data of NVC422 for Impetigo skin infection 2H 2012
NGSX 0.92 Advisory Committee 02/09/2012 Anesthetic and Analgesic Drug Products Advisory Committee meeting Feb 9 2012 to review Qutenza NDA for neuropathic pain related to HIV-associated peripheral neuropathy
NGSX 0.92 PDUFA 03/07/2012 PDUFA 3/7/12 of Qutenza for Neuropathic pain associated with HIV-associated peripheral neuropathy (HIV-PN)
NLNK 6.48 Phase 2 12/31/2011 Phase 2 first data for melanoma 4Q 2011
NLNK 6.48 Phase 2 06/30/2012 Phase 2b/3 initiation of NSCLC 1H 2012
NLNK 6.48 Phase 3 12/31/2012 Interim Phase 3 pancreatic cancer data due late 2012
NPSP 6.80 NDA filing 12/31/2012 File NDA NPSP558 for Hypoparathyroidism sometime during 2012
OGXI 12.48 Phase 2 12/31/2012 Phase 2 data of Custirsen for prostate cancer due sometime 2012
OMER 5.53 Phase 3 03/31/2012 Phase 3 data of OMS302 for intra-ocular lens replacement surgery due 1Q
OMER 5.53 Phase 3 06/30/2012 Phase 3 OMS103HP for arthroscopy data due mid 2012
ONTY 6.78 Phase 3 03/31/2012 Phase 3 interim data of Stimuvax for NSCLC due 1Q 2012
OREX 2.05 06/30/2012 Expect to initiate cardiovascular outcomes trial 1H 2012 for Contrave for obesity
OXGN 1.05 Phase 3 12/31/2012 Possible initiation of Phase 3 ZYBRESTAT clinical program in anaplastic thyroid cancer (ATC) in 2012
PATH 2.32 NDA filing 06/30/2012 Resubmit NDA for migraine patch 1H 2012
PCYC 16.55 Phase 2 03/31/2012 Phase 2 complete enrolment of PCI-32765 for relapsed or refractory MCL Q1 2012
PCYC 16.55 Phase 2 03/31/2012 Phase 2 PCI-32765 for Diffuse Large B-cell Lymphoma (DLBCL), complete enrolment 1Q (1106)
PCYC 16.55 Phase 2 03/31/2012 Phase 2 PCI-27483 for pancreatic cancer complete enrolment 1Q 2012
PGNX 8.51 PDUFA 04/27/2012 PDUFA 4/27/12 for subcutaneous RELISTOR for chronic pain
PGNX 8.51 NDA filing 06/30/2012 NDA filing of Oral Methylnaltrexone for Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation due mid 2012
PLX 5.63 PDUFA 05/01/2012 PDUFA 5/1/12 of Taligluerase for Gaucher disease, 3mth delay
POZN 4.21 Phase 3 06/30/2012 Complete Phase 3 2012 of PA32540 for secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers 1H 2012
POZN 4.21 NDA filing 09/30/2012 File NDA 3Q 2012 of PA32540 for secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers
PPHM 0.91 Phase 2 06/30/2012 Phase 2 Data Bavituximab for Refractory NSCLC to be unblinded 1H 2012
PPHM 0.91 Phase 2 06/30/2012 Phase 2 interim Data Bavituximab for pancreatic cancer due sometime during 2012
PPHM 0.91 Phase 2 12/31/2012 Phase 2 final Data Bavituximab for first line NSCLC due sometime 2012
PTN 0.46 Phase 2 12/31/2012 Phase 2b data of bremelanotide for female sexual dysfunction (FSD) 2H 2012
QLTI 6.96 Phase 2 03/31/2012 Phase 2 initiation of Glaucoma 1Q '12
RIGL 8.16 Phase 2 06/30/2012 Phase 2 initiation of R343 for asthma mid 2012
RIGL 8.16 Phase 2 12/31/2012 Phase 3 interim data of Fostamatinib for rheumatoid arthritis due 2H 2012
RNN 0.42 Phase 2 06/30/2012 Phase 2b initiation of Zoraxel for erectile dysfunction 1H 2012
RPTP 6.27 Phase 2b 03/31/2012 Initiate Phase 2b solid caplet formulation of DR Cysteamine in NASH 1Q 2012
RPTP 6.27 NDA filing 03/31/2012 NDA filing of RP103 for Nephropathic Cystinosis due 1Q 2012 seeking 6-month priority review
SCMP 4.42 Phase 3 12/20/2011 Phase 3 data Opioid-induced bowel dysfunction expected mid-late December
SLXP 49.56 PDUFA 04/27/2012 PDUFA 4/27/12 for subcutaneous RELISTOR for chronic pain
SNSS 1.29 Phase 3 06/30/2012 Phase 3 interim analysis of vosaroxin in combination with cytarabine in first relapsed or refractory AML, in mid-2012
SNTA 4.61 Phase 1b/2 03/31/2012 Initiate Phase 1b/2 rectal cancer trial 1Q 2012
SNTA 4.61 Phase 2 06/30/2012 Phase 2b/3 interim data of Ganetespib for NSCLC due 2Q 2012
SNTA 4.61 Phase 2 12/31/2012 Phase 2b initiation of elesclomol in NSCLC sometime during 2012
SNTS 4.54 Phase 3 09/30/2012 Phase 3 Rhucin for Hereditary Angioedema (HAE) attacks to be completed 3Q 2012
SPPI 15.17 NDA filing 12/31/2012 Rolling NDA filing of Belinostat for Peripheral T-Cell Lymphoma due sometime in 2012
SPPI 15.17 Phase 3 12/31/2012 Phase 3 Topline data + NDA filing for Apaziquone for bladder cancer sometime in 2012
STEM 0.79 03/31/2012 Phase 1 HuCNS-SC cells Data for PMD due early 2012
THLD 1.50 Phase 2 02/22/2012 Phase 2 topline data Pancreatic Cancer mid-late Feb 2012 - Feb 22 estimate only
THLD 1.50 Phase 3 12/31/2012 Phase 3 interim data of TH-302 for soft tissue sarcoma due end of 2012
THRX 18.10 NDA filing 06/30/2012 NDA filing of Relovair for chronic obstructive pulmonary disease (copd) due mid 2012
TLON 0.74 PDUFA 05/13/2012 PDUFA 5/13/12 for Marqibo for 2nd line adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)
TSRX 5.33 Phase 3 03/31/2013 Phase 3 data of second trial of torezolid phosphate for ABSSSI due early 2013
VICL 3.67 Phase 3 06/30/2012 Phase 3 initiation of TransVaxT CMV vaccine for HCT patients during 1H 2012
VICL 3.67 Phase 2 06/30/2012 Phase 2 initiation of TransVaxT CMV vaccine for solid organ transplant (SOT) patients during 1H 2012
VICL 3.67 Phase 3 06/30/2012 Phase 3 topline data Allovectin-7 for melanoma mid 2012
VICL 3.67 Phase 3 12/31/2012 Phase 3 initiation of Collategene for Peripheral arterial disease sometime 2012
VTUS 8.10 Phase 3 05/15/2012 Data due 2Q 2012 of Phase 3 European trial of VEN 307 (diltiazem cream) for Anal fissures
VTUS 8.10 Phase 3 06/15/2012 First of two Phase 3 trials of VEN 309 (iferanserin) for Symptomatic hemorrhoids. Data due June 2012.June 15 midpoint estimate only
VVUS 12.20 Advisory Committee 02/22/2012 Advisory Committee meeting for Qnexa for obesity under limited indication Feb 22 2012
VVUS 12.20 PDUFA 04/17/2012 PDUFA 4/17/12 of Qnexa for obesity
VVUS 12.20 PDUFA 04/29/2012 PDUFA 4/29/12 of Avanafil for Erectile dysfunction
XNPT 4.34 PDUFA 06/09/2012 PDUFA 6/9/12 for sNDA of Horizant for post-herpetic neuralgia (PHN)
XOMA 1.72 Phase 3 06/30/2012 Phase 3 initiation of Behcet's uveitis 2Q 2012
YMI 1.62 Phase 3 12/31/2011 Phase 3 adult glioma efficacy data due 2H 2011
YMI 1.62 Phase 1/2 06/30/2012 Phase 1/2 Prelim data of CYT997 in glioma expected 1H 2012
YMI 1.62 Phase 3 06/30/2012 Phase 3 initiation of CYT387 for Myelofibrosis planned mid 2012
ZGNX 2.57 NDA filing 04/30/2012 NDA filing of Zohydro for moderate to severe pain early 2Q 2012
ZIOP 5.10 Phase 3 03/31/2012 Phase 3 enrolment of palifosfamide for metastatic soft tissue sarcoma due to be completed 1Q 2012
ZIOP 5.10 Phase 3 12/31/2012 Phase 3 data of palifosfamide for metastatic soft tissue sarcoma due 2H 2012
ZIOP 5.10 Phase 3 12/31/2012 Phase 3 initiation of palifosfamide for small cell lung SCLC during 2H 2012
ZIOP 5.10 Phase 2 12/31/2012 Phase 2 initiation of GRN1005 for GBM 2012
ZLCS 1.17 Phase 2 12/31/2012 Phase 2b topline data of of Synavive in Rheumatoid Arthritis 2H 2012

Welcome To The World of Biotechnology, The Future of Successful Stock Trading!

Bio-tech Trades.info reports and subscription services are complied and designed for Bio Tech, Options, and Forex Traders!  Biotech Traders.Info compiles its reports and subscription service for Bio-Tech, Options and Forex traders, brokers, dealer, money managers, hedge fund managers, investment advisors and investment bankers! You can make trades with our seasoned traders, making entries and exits like large money center banks. Our trader reports and subscription services can allow you to take control of your trades to maximize your trading Success!  No More Trading Blind in this Mixed Up, Manipulated Market!  With our reports and subscriptions you will be able to make planned, relaxed and predictable trades which will result in safer trades with explosive returns!    We Give You The Trade!   We Give You the What, When and How to Enter the Trade!  We are sure if you follow our report or subscription, Follow Our #1 Rule of Watching for Volume as Your #1 Indicator to Entering a Trade, You Will Increase Your Successful Trades as Much as 50% With Little Effort. 

FDA CALENDAR

Welcome to the Forex Trading Store

FOREX ROBOT!

We did not believe this until we tried it ourself!  We allowed this program (THE FOREX TRADING ROBOT) to trade $10,000.00 in one of our accounts; IT ACTUALLY  WORKED! They Call it the Automated Forex Trading System Robot! This is one Im Refering to you. Forex Traders You Should Check This Out! Matt Cohen Pip Gainers. 

$1000 to $1.4 Million in just 13 Months! Discover the Secrets to Investing In Penny Stocks. Learn how to Discovers stocks that TRIPLE in a matter of Days!

Turn $1000 Into $25,220 ... In Just 4 Months!   "Don't Take our Word For it - Here's the ABSOLUTE, UNDENIABLE PROOF!"

Losing money in the market can quickly destroy confidence.My system can allow you to trade with 100% confidence because instead of hoping to make a profit by guessing what to do, you'll have a plan. Your success in your investment business depends on only one thing: The decisions YOU make. The only way for you to make the right decisions is by having superior knowledge and information. Once you understand how to REALLY make money, you can trade with total confidence.

This Forex System is not another black-box trading system - we're offering you a full Forex training program so you actually learn how to trade as opposed to blindly follow the signals generated by a black box system.  There's an important difference! When you simply follow a system you don't quite understand the trading decisions you're taking... you just follow the signals generated by a combination of indicators that may or may not be right at that precise time.  In the order hand, when you actually learn how to trade you can fully understand why this or that trading decision is considered and why this or that action is undertaken!

Forex Trading For Winners. Take Your Trading To A New Level With Stealth Forex Trading Systems. The Very Best Forex Investment That You Can Make. No matter whether you are a complete novice or experienced in currency day trading, this exciting, low cost, easy to follow forex trading software, complete with Custom Forex Indicators can help to enhance your trading performance.

A Division of Affiliate Information Technology

Great Traders Trade Information!

   Forex Robots

 

• GPS Forex Robot
• The Traders Mindset Video Set
aaaaaaaaaaaaiii